

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

USA

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/705, 19/00, C12N 15/62, A61K 38/17	A1	(11) International Publication Number: WO 95/26985 (43) International Publication Date: 12 October 1995 (12.10.95)
(21) International Application Number: PCT/US95/04221 (22) International Filing Date: 5 April 1995 (05.04.95) (30) Priority Data: 08/224,593 5 April 1994 (05.04.94) US (71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US). (72) Inventors: BEUTLER, Bruce, A.; 6181 Preston Haven Drive, Dallas, TX 75230 (US). BAZZONI, Flavia, M.; Apartment #2345, 6445 Shady Brook Lane, Dallas, TX 75206 (US). (74) Agent: KITCHELL, Barbara, S.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: MODIFIED RECEPTORS THAT CONTINUOUSLY SIGNAL (57) Abstract Engineered cell surface receptors are described that are constitutively active in the absence of the cytokine, hormone or molecule that normally activates the receptor. Receptors that constitutively signal are generally created by engineering the receptor to form multimers at the cell surface. Disclosed are various DNA, protein and cellular compositions and methods of making and using such constitutively active receptors. Particular examples are fusion proteins in which the stem, transmembrane domain and cytoplasmic domain are derived from a TNF receptor, and the extracellular, multimerizing domain is derived from an erythropoietin receptor. Transfection of such fusion protein constructs into cells is shown to result in a strong cytotoxic effect.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

DESCRIPTIONMODIFIED RECEPTORS THAT
CONTINUOUSLY SIGNAL

5

BACKGROUND OF THE INVENTION1. Field of the Invention

10 The present invention relates generally to the
fields of cell surface receptors and their functions.
More particularly, it concerns the generation of
engineered receptor molecules that are constitutively
active in the absence of the cytokine, hormone or
15 molecule that normally activates the receptor. Disclosed
are various DNA, protein and cellular compositions and
methods of making and using constitutively active
receptors, particularly, receptors engineered to form
multimers.

20

2. Description of the Related Art

 Cytokines are a group of peptide hormones that
interact with cell surface receptors to signal specific
25 biological effects. The tyrosine kinase receptors have a
consensus tyrosine kinase sequence in the cytoplasmic
domain that is involved in the signal transduction
mechanism. Other types of receptors signal by mechanisms
that are less well understood, although there is evidence
30 for tyrosine phosphorylation in some receptors.

 The erythropoietin receptor (EPOR) recognizes a
glycoprotein hormone ligand. This hormone
(erythropoietin) is required for the survival,
35 proliferation and differentiation of committed erythroid
progenitors. Other members of the cytokine family to
which this receptor belongs include the receptors for

- 2 -

hematopoietic growth factors such as interleukins, colony-stimulating factors and growth hormones. Unlike the tyrosine kinase receptors, the mode of signalling activity of these cytokine receptors is not known.

5 However, it has been suggested that dimerization or oligomerization of these receptors plays an important role in the signal mechanism (Oyashi et al., 1994).

10 Previous studies have also shown that a mutation in the EPOR which converts an arginine to cysteine at position 129 confers constitutive expression and induces stable receptor homooligomers (Oyashi et al., 1994; Longmore and Lodish, 1991). Chimeric receptors have also been expressed by the same group in which the cytoplasmic and extracellular domains of the EPOR and the epidermal growth factor receptor (EGFR), a tyrosine kinase
15 receptor, have been fused to form chimeric receptors that respond to the extracellular domain ligand by the response mechanism of the cytoplasmic domain.

20

Tumor necrosis factor (TNF) is a cytokine mediator which initially showed much promise as an antineoplastic agent, since the protein specifically destroys transformed cells *in vitro*, and causes the hemorrhagic
25 necrosis of transplantable tumors *in vivo* without killing normal cells. Subsequently, however, it was demonstrated that TNF has many toxic effects in living animals. Specifically, it appears to be a central mediator of endotoxic shock. Unfortunately, this has limited the
30 therapeutic application of TNF. No human tumor has ever been successfully treated with the protein.

All of the biological effects of TNF are mediated by two types of cell membrane receptor. The larger of
35 these, a 75 kD glycoprotein, transduces the proliferative effect of TNF, although some cytotoxic activity may be generated through this molecule as well. The smaller

- 3 -

receptor, a 55 kD cell surface glycoprotein, bears some homology to the larger TNF receptor in the region of the extracellular domain, but has an entirely different cytoplasmic domain. It therefore generates a different
5 signal when activated by ligand binding. It is the 55 kD cell surface receptor that appears to be chiefly responsible for the induction of TNF-mediated cytotoxicity.

10 TNF is a trimeric molecule. The TNF receptors exist as a mixed population of monomers on the surface of virtually all somatic cells. TNF initiates signals through both of the two types of receptor by cross-linking three identical monomeric subunits (either three
15 75 kD subunits or three 55 kD subunits) on the cell surface. The juxtaposition of the monomers leads to generation of a signal through a process that is not completely understood. It is clear, however, that the cross-linking of monomers, and not the engagement of TNF
20 *per se*, is the important event in signal transduction. Therefore, anti-receptor antibodies can substitute for TNF, generating an agonist signal. There still exists a need however, for a mechanism of inducing the cytotoxic TNF response without inducing the side effects that are
25 caused by administration of TNF.

SUMMARY OF THE INVENTION

The present invention, in a general and overall
30 sense, concerns engineered receptor molecules capable of constitutively signalling, i.e., receptors that exert or induce a biological function or reaction even in the absence of the ligand that normally induces the receptor to signal a positive response. The invention arises from
35 the surprising discovery that the formation of multimeric receptor complexes on the extracellular surface is sufficient for transmitting a positive signal to the

- 4 -

cytoplasmic domain of the receptors even in the absence of the cognate ligand or in the presence of a ligand that has entirely different activities. For clinical use, a ligand with minimal extraneous effects would be selected.

5

The receptors used in the practice of the invention are preferably cytokine receptors and have three basic parts, the extracellular domain, the cytoplasmic domain and the transmembrane domain. The extracellular domain functions to recognize and bind the ligand. Binding of the ligand induces the receptors to form dimers, trimers or higher order multimers. The presence of the multimeric receptors then transmits a signal through the transmembrane domain to the cytoplasmic domain which mediates a biological response.

15

The present inventor(s) has(ve) discovered that a chimeric receptor which comprises an extracellular domain that is capable of forming multimeric complexes may be joined to a cytoplasmic domain from a different receptor, and that the signal is transmitted and results in a biological response. In the examples disclosed herein, the transmembrane domain is derived from the same receptor as the cytoplasmic domain, however, it is contemplated that any of several receptor transmembrane domains would function in the chimeric receptors and would be included within the scope of the present invention. For example, the transmembrane domain may be derived from the same receptor as the extracellular domain, or it may even be derived from a different receptor than either the extracellular or cytoplasmic domain. Alternatively, the transmembrane domain may be encoded by a chemically synthesized DNA fragment based on consensus transmembrane domain sequences.

25

30

35

In a preferred embodiment, the present invention is a polypeptide comprising a cytokine receptor cytoplasmic

- 5 -

domain functionally connected to an extracellular domain. The extracellular domain is capable of forming multimers and stimulating constitutive signal activity in the cytoplasmic domain. One aspect of the invention is an
5 extracellular domain that forms multimers in the absence of any signal such as the binding of a ligand. Examples of this type of domain are the tumor necrosis factor receptor extracellular domain directly linked to the tumor necrosis factor ligand, or the mouse erythropoietin
10 extracellular receptor which contains an arginine to cysteine mutation at position 129. It is understood that any such extracellular domain covalently complexed to the cognate ligand, or an extracellular receptor domain/antibody complex, or any extracellular domain that
15 contains a mutation that confers the spontaneous formation of multimers would be encompassed by the present claimed invention. Other examples include, but are not limited to receptors for growth hormones and the interferons. Moreover, the extracellular domain
20 responsible for multimer formation need not be derived from a receptor. Portions of the immunoglobulin heavy chain, influenza hemagglutinin and other proteins that multimerize, either in the extracellular compartment or within the cytosol are contemplated to be useful in the
25 design of molecules that exhibit constitutive signalling activity.

The receptor cytoplasmic domain of the present invention determines the biological response to the
30 signal. Any type of receptor domain that responds to the formation of multimers is an acceptable embodiment of the present invention. A preferred domain is the cytoplasmic domain of the tumor necrosis factor receptor, and more particularly, the cytoplasmic domain from the 55 kDa or
35 the 75 kDa tumor necrosis factor receptors. Other receptors that confer different biological activities are also contemplated to be encompassed by the present

- 6 -

claimed invention. Examples of such receptors include, but are not limited to the Fas antigen, growth hormone receptor, insulin receptor and erythropoietin receptor cytoplasmic domains.

5

In certain embodiments, the present invention is an expression vector construct comprising a DNA sequence encoding the amino acid sequence in accordance with SEQ ID NO:7. By an expression vector is meant a segment of
10 DNA that comprises one or more structural genes, functionally connected to the necessary promoter/enhancer regions, ribosome binding sites and polyadenylation sites necessary for the production of polypeptide products in a cell, and preferably in a eukaryotic cell. The
15 expression vector further comprises an origin of replication and other DNA segments necessary for its own replication in a cell.

The expression vector construct may further include
20 a DNA segment encoding a polypeptide comprising a cytokine receptor cytoplasmic domain functionally connected to an extracellular domain as the structural gene. In this embodiment, the vector directs the expression of a chimeric receptor construct that is
25 capable of forming multimers and conferring constitutive signal activity.

In a further embodiment, the invention is a method of inducing a cytotoxic effect in a cell. The method
30 comprises obtaining an expression vector construct comprising a cytokine receptor with constitutive signal activity and expressing the cytokine receptor in a cell. The signal confers a cytotoxic reaction. A preferred
35 signal activity is the tumor necrosis factor receptor activity.

- 7 -

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

10 FIG. 1A. 3T3 cells transfected with the chimeric TNF receptor (T●R) expression construct, before cycloheximide treatment. Little or no morphologic change is detectable.

15 FIG. 1B. Non-transfected 3T3 cells before cycloheximide treatment. Little or no morphologic change is detectable.

20 FIG. 1C. 3T3 cells transfected with the chimeric TNF receptor (T●R) expression construct, after cycloheximide treatment. Transfected 3T3 cells were treated with cycloheximide for a period of 4 hours. Note that most of the cells are lysed.

25 FIG. 1D. Nontransfected 3T3 cells, after cycloheximide treatment. Nontransfected cells were treated with cycloheximide for a period of 4 hours. Little or no morphologic change is detectable.

30 FIG. 2. Oncogenicity of the constitutively active 55 kD TNF receptor (T●R) construct. When transfected into NIH 3T3 cells, four independent clones expressing the chimeric messenger RNA were isolated and inoculated into the right flank of nude mice. These animals (the top-most four mice) developed large tumors. Animals
35 inoculated with 3T3 cells that were transfected with an

- 8 -

empty version of the expression vector did not develop tumors (bottom mouse in the photograph).

FIG. 3 shows the binding of 125 -labeled Epo to
5 chimeric, truncated, and wild-type Epo receptors
expressed in COS cells following transfection with
expression constructs encoding these molecules. Binding
was allowed to occur in the presence (+) or the absence
(-) of unlabeled Epo at a 60 nM concentration. Control
10 cells were transfected with empty vector (pCMV4). The
truncated receptor is identical to the wild-type and
chimeric in the extracellular domain, except that it
lacks cytoplasmic domain for signal transduction.

15 FIG. 4 shows the immunoprecipitation of Epo
receptors expressed by the same COS cells described in
FIG. 3 where I is the immune serum, P the pre-immune
serum. The major immunoprecipitable bands representing
the chimeric receptors and wild-type receptor are of the
20 same size, approximately 60 kDa, whereas the band
representing the truncated receptor is about 35 kDa, as
indicated by the arrows.

FIG. 5A shows PAM 212 cells cotransfected with a
25 vector encoding β -galactosidase and the empty pCMV
vector. Blue cells are larger and more numerous than the
cells cotransfected with β -galactosidase and pCMV vectors
containing either of the 55 kDa or 75 kDa chimeric
receptors.

30

FIG. 5B and FIG. 5C show apoptosis induced by
transfection with the chimeric Epo\TNFR expression
constructs. FIG. 5B shows PAM 212 cells cotransfected
with β -galactosidase and the pCMV vector containing a 55
35 kDa chimeric receptor construct. FIG. 5C shows PAM 212
cells cotransfected with a vector encoding β -

- 9 -

galactosidase and the pCMV vector containing a 75 kDa chimeric receptor construct.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

5

It was an objective of the disclosed studies to identify multimerizing groups that might be used to create constitutive signalling activity. Multimeric and constitutively active forms of 55 kDa and 75 kDa forms of
10 TNF as well as TNF itself and the extracellular domain of influenza hemagglutinin were tested. Both TNF and the influenza hemagglutinin are homotrimeric proteins in their native state. Additionally, the erythropoietin receptor extracellular domain was employed as a
15 multimerizing group, with the expectation that this protein should dimerize in the presence of erythropoietin, in view of a previously described mutant dimeric form of the receptor.

20 A soluble form of TNF was observed, rather than the multimerizing forms expected. Surprisingly, malignant transformation of NIH 3T3 cells transfected with an expression construct coding for a secreted, soluble variant of TNF was observed.

25

The use of influenza hemagglutinin as a multimerizing group did not yield detectable cell surface expression of protein when the cytoplasmic domain of the TNF receptors was attached. This was surprising since
30 truncated variants of the influenza hemagglutinin molecule, lacking any cytoplasmic domain were expressed at the cell surface.

High levels of chimeric TNF/EpoR protein were
35 expressed at the cell surface and constitutive signal transduction was detected through the TNF cytoplasmic domain. Erythropoietin receptor extracellular domain was

- 10 -

successfully used not only as a multimerizing group, but also the chimeric fusion proteins were active even in the absence of added ligand.

5 The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to
10 function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are
15 disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE I

20 TNF-RECEPTOR:TNF LIGAND GENE CONSTRUCTION

 This examples describes the generation of a genetic construct that directs the expression of a protein in which the TNF ligand is coupled to the extracellular
25 domain of the TNF receptor, but which does not contain a cytoplasmic domain.

 From genomic DNA, the entire TNF coding sequence and introns (excluding the TNF 5'-UTR and 3'-UTR sequences)
30 was amplified by polymerase chain-reaction (PCR). The stop-codon of the TNF gene was omitted, and the terminal codon (for leucine) was spliced to a sequence encoding the extracellular domain of the TNF 55 kD receptor beginning just above the plasma membrane in the protein
35 sequence, and continuing through the C-terminus. An aspartic acid residue was interposed to assure the formation of a salt bridge with Lysine-11 of each

- 11 -

subunit, permitting stable trimer formation. A cDNA clone was used for this part of the amplification.

The construct produced by recombinant PCR coded for a molecule that is exteriorized under the influence of the TNF secretory signal peptide. The molecule formed a homotrimer, based on the association of TNF monomers. The extracellular "stem" acts as a spacer, to give enough flexibility to avoid tension on the TNF trimer.

The same type of construction was applied to produce a constitutive form of the 75 kD TNF receptor. As before, the TNF gene, and the receptor cDNA, were used to produce the recombinant molecule, in which an aspartic acid residue follows the C-terminal residue of the TNF monomer. These constructions were made using mouse sequences; however, the same methodology may be straightforwardly applied to the human genes and their products. The mouse provides a useful *in vivo* model.

After synthesis of this construct, a frame-shift mutation was detected within the expression unit. This was expected to cause termination of the protein prior to synthesis of the cytoplasmic domain; however, as shown in Example II, biological activity was detected.

EXAMPLE II

CHARACTERIZATION OF TNF-RECEPTOR:TNF CONSTRUCT

The gene described in Example I, expressing a chimeric protein without a cytoplasmic domain, was transfected into cells *in vitro*. The gene was transcribed, leading to the production of high levels of chimeric messenger RNA in the cytoplasm of transfected cells.

- 12 -

The protein was not detected using immunostaining techniques, in which rabbit anti-mouse TNF antibody was applied to the transfected cells, followed by a washing step and application of a secondary antibody of caprine origin (goat anti-rabbit IgG) coupled to fluorescein. However, secreted TNF activity was detected in the culture medium of transfected cells employing the L-929 bioassay system. Briefly, culture medium was harvested and added at various dilutions to monolayers of L-929 cells grown at a density of 70,000 cells per well of a 96-well plate. Cycloheximide was added to the assay system at a concentration of 0.1 mg/mL. The cells were allowed to incubate for 16 hours at 37°C in a humidified CO₂ incubator, after which time residual cells adherent to the plastic were stained with crystal violet and quantified by densitometry. Moreover, there was evidence that the chimeric molecule produced had biological activity, despite the frame-shift mutation. The engineered molecule, though lacking a cytoplasmic domain, caused rapid destruction of transfected NIH 3T3 fibroblasts when cycloheximide was added to the culture (FIG. 1). As such, the molecule still mimicked the effect of TNF itself, providing evidence that the expressed mutant protein has certain functional activities.

The presence of soluble TNF activity in the culture medium suggested that the truncated protein was a secreted product, rather than a membrane-anchored product.

EXAMPLE III

TNF-RECEPTOR:TNF CONSTRUCT ONCOGENIC ACTIVITY IN VIVO

A surprising new activity of the chimeric molecule was discovered when cells expressing the construct were administered to mice. These studies showed that the

- 13 -

modified partial receptor:ligand molecule was highly oncogenic.

Even when very low levels of the chimeric messenger RNA of Example I were expressed in stably transfected NIH 3T3 cells, the cells formed large tumors in nude mice in a matter of days (FIG. 2). This phenomenon was observed in 8 out of 8 mice, inoculated with four separate clones expressing the recombinant proteins. None of the control animals (receiving cells transfected with empty vector) developed tumors. Thus, the signal generated by the recombinant protein is capable of transforming cells.

However, owing to the fact that this engineered molecule may be a secreted product, rather than a membrane-anchored product, it was not established whether the oncogenic effect is transduced by the 75 kD receptor, the 55 kD receptor, or both receptors acting in conjunction with one another.

The inventor contemplates that it is possible that certain cancers are caused by this type of rearrangement, involving the TNF receptor or other cytokine receptors, *in vivo*. This example provides a model for studying the formation of tumors.

EXAMPLE IV

CHIMERIC TNF RECEPTOR:HEMAGGLUTININ CONSTRUCTS

The inventor has investigated the use of a "multimerizing group" other than TNF to maintain the cytoplasmic domains in close proximity.

The influenza hemagglutinin (a trimeric protein) was first employed as the extracellular domain, on the assumption that it would maintain three cytoplasmic domains of the TNF receptors in close proximity with one

- 14 -

another. The relevant constructs were made and expressed within COS cells. The native influenza hemagglutinin construct, as well as a construct containing only a few amino acids on the cytoplasmic side, were well expressed at the cell surface, as assessed by the ability of transfected cells to form rosettes with erythropoietin. On the other hand, the full length construct apparently was not expressed at high levels in a native form at the cell surface, apparently because of failure to fold properly. Furthermore, no cytotoxic effect was observed on transfection of the hemagglutinin chimeras.

EXAMPLE V

CHIMERIC TNF RECEPTOR:ERYTHROPOIETIN RECEPTOR CONSTRUCTS

The next extracellular moiety investigated was the erythropoietin receptor. Fusion proteins were constructed using the erythropoietin receptor as the extracellular domain, together with the cytoplasmic domains of the two TNF receptors.

In these studies, four types of recombinant molecule were produced. The extracellular domain was derived either from the wild-type mouse erythropoietin receptor (EpoR), or from a mutant receptor in which an arginine to cysteine substitution at residue 129 results in spontaneous dimerization (Li et al., 1990). The "stem," transmembrane domain, and cytoplasmic domain of each recombinant was derived either from the 55 kD or 75 kD TNF receptor. The approach was to amplify and clone each component separately, sequence the fragments to ensure that no mutation was introduced, and then splice the fragments together using a restriction sites built into the primers used for amplification.

35

- 15 -

1. Amplifications

For the EpoR signal peptide and extracellular domain, the 5' EpoR primer used had the sequence of SEQ ID NO:1 (Kpn-I site underlined). This primer hybridizes with the 5'-untranslated region of the EpoR cDNA. The 3' EpoR primer for the EpoR signal peptide and extracellular domain had the sequence of SEQ ID NO:2 (Hind-III site underlined).

10

CGT GGT ACC TGA GCT TCC TGA AGC GGC (SEQ ID NO:1)

GGA CCT AAG CTT CAGG GTC CAG CTC GCT AGC GGT (SEQ ID NO:2)

15

These primers were used for amplifying extracellular domains from both wild type and mutant EpoR clones (obtained from Dr. S. Watowich, Massachusetts Institute of Technology, Boston, MA). The mutant EpoR clones had a mutation of arginine to cysteine at residue 129. The entire extracellular domain was amplified, encompassing the initiator methionine and continuing up to the last extracellular residue (no. 249). The amplification product encodes 24 amino acids of propeptide, plus 225 amino acids of the mature protein. The human erythropoietin receptor DNA sequence is found in Genbank, accession number J04843, incorporated herein by reference.

30

The TNF receptor sequences are available in Genbank, as accession number M59378 for the 75k and accession number M59377 for the 55 k DNA segments, herein incorporated by reference. For the 55 kD TNF receptor "stem," transmembrane domain, and cytoplasmic domain, the 5' primer used had the sequence of SEQ ID NO:3 (Hind-III site underlined); and the 3' primer had the sequence of

35

- 16 -

SEQ ID NO:4 (Xba-I site underlined; stop codon in bold).

GGA CCT AAG CTT CCT CCG CTT GCA AAT GTC ACA (SEQ ID NO:3)

5 GCT CTA GAG CTT ATC GCG GGA GGC GGG TCG TGG A (SEQ ID NO:4)

10 These primers were used for amplifying the 55 kD TNF receptor stem, transmembrane domain and cytoplasmic domain from nucleotide 687 to the stop codon at nucleotide 1460, incorporating 15 extracellular domain residues in the stem, 23 transmembrane domain residues and 219 cytoplasmic domain residues, for a total of 257 residues.

15

For the 75 kD TNF receptor "stem," transmembrane domain, and cytoplasmic domain, the 5' primer used had the sequence of SEQ ID NO:5 (Hind-III site underlined); and the 3' primer used had the sequence of SEQ ID NO:6 (Xba-I site underlined; stop codon in bold).

20

GGA CCT AAG CTT CCA AGC ATC CTT ACA TCG TTG (SEQ ID NO:5)

GCT CTA GAT CAG GCC ACT TTG ACT GCA AT (SEQ ID NO:6)

25

30 These primers were used for amplifying the 75 kD TNF receptor stem, transmembrane domain and cytoplasmic domain from nucleotide 757 to stop codon at nucleotide 1467, incorporating 20 extracellular domain residues in the "stem", 29 transmembrane domain residues, and 187 cytoplasmic domain residues for a total of 236 residues.

2. Cloning

35

All components were cloned into Bluescript-KS, and sequenced independently using the Sanger dideoxynucleotide method. The fragments were then cloned

- 17 -

Kpn-I to Hind-III (for the EpoR coding regions) and Hind-III to Xba-I (for the TNFR coding regions) into the vector pCMV4 for expression. The full-length EpoR construct was also cloned into pCMVr for expression as a control in some studies.

For constructs containing either the wild-type or mutant EpoR domain, the predicted junctional amino acid sequences are as follows:

55 kD:L-D-P-(F-E-L)-P-P-.... (SEQ ID NO:7)

75 kD:L-D-P-(F-E)-P-S-I... (SEQ ID NO:8)

The underlined amino acids are derived from the Epo receptor. The amino acids in parentheses are artificially introduced. The remaining amino acids represent the start of the TNF receptor moiety.

EXAMPLE VI

CHARACTERIZATION OF CHIMERIC TNF:ERYTHROPOIETIN RECEPTORS

1. Detection of Expression of Chimeric Proteins on the Plasma Membrane by Measurement of Epo Binding

Radiolabeled (^{125}I) Epo was obtained from NEN. 2×10^6 COS cells were plated in a 10 cm plate, transfected according to a CaPO_4 method (Chen & Okayama, 1987), using 20 μg of total DNA purified by the Quiagen technique.

Transfections were performed in duplicate plates, from which the cells were pooled after 12 hours. The cells were then split into triplicate wells of a six-well plate at a density of 1×10^6 per well. After five hours allowed for adherence to the plastic, cells were incubated on ice in 1 ml of medium containing 2% serum and 2% antibiotic mixture (pen/strep/GIBCO), 25 mM HEPES buffer, and 0.525 pM iodinated Epo (415 nCi/ml).

- 18 -

Incubation was allowed to continue for 2 hours with occasional gentle shaking by hand (on ice). 3 ml of ice-cold PBS containing 1 mM EDTA was then added to each well. The cells were harvested by trituration, pelleted, transferred to Eppendorf tube, and washed once more with PBS/EDTA solution (all procedures were carried out in the cold). The cell pellets were then counted for bound radioactivity.

As illustrated in FIG. 3, transfection with the chimeric or wild-type Epo receptors led to greatly augmented Epo binding. The introduction of competing unlabeled Epo essentially abolished binding, demonstrating the specificity of the interaction. The fact that labeled Epi is capable of binding tightly and specifically to intact transfected cells indicates that the recombinant molecules are expressed on the plasma membrane of the cells. The fact that far more Epo is bound by recombinant forms of the receptor, compared with the native form of the Epo receptor, suggests that the recombinant molecules may exhibit higher affinity for the ligand, or a faster on-rate, than the native molecule. This is particularly likely in view of the fact that similar quantities of the native and recombinant receptors were expressed, as shown by immunoprecipitation studies.

2. Immunoprecipitation Studies

To further characterize the molecules that were expressed, immunoprecipitation analysis of ^{35}S -labeled proteins was performed. 2×10^6 COS cells were transfected in two 10 cm plates as described above. Cells were pooled and replated as described above after 12 hours. After adherence, cells were washed in methionine/cysteine-free medium and allowed to incubate in 3 ml of the same medium for one hour. Fresh

- 19 -

methionine/cysteine-free medium (1 ml per well), supplemented with 100 μ Ci of 35 S translabel (ICN), was then added to each monolayer. Cells were allowed to incubate in the presence of the label for 3 hours. They were then collected by trituration in PBS/EDTA solution.

The cells were then pelleted, and resuspended in an Eppendorf tube in 250 μ l of lysis buffer (0.15 M NaCl, 50 mM tris/HCl, pH 7.4, 1 mM EDTA, and 1.0% triton X-100). Nuclei were removed by centrifugation, and the supernatants were transferred to a tube containing an equal volume of the same lysis buffer, to which 1.0% sodium deoxycholate and 0.2% SDS had been added.

Rabbit antiserum raised against the NH_2 terminus of the EpoR (5-10) was added at a dilution of 1:250. A non-immune serum was used as a control. Antibody was allowed to incubate overnight at 4°C with gentle agitation. Pansorbin was then added to each tube, and allowed to react for 2 hours under the same conditions. The pansorbin was washed five times with lysis buffer, with one final wash in PBS alone (all washes on ice). The pansorbin was then resuspended in reducing SDS sample buffer, boiled, and the supernatant subjected to electrophoresis in a 10%-15% polyacrylamide gradient gel under denaturing conditions. Results are shown in FIG. 4 using 35 S-labeled proteins from transfected COS cells immunoprecipitated with anti-EpoR antisera.

30

EXAMPLE VII

ACTIVITY OF CHIMERIC TNF:ERYTHROPOIETIN RECEPTORS

Convincing evidence of the biological activity of the chimeric TNF:EPOR proteins was also obtained from expression in mammalian cells. Cytotoxic activity was demonstrated in two ways.

- 20 -

First, PAM 212 cells (transformed mouse keratinocytes) were cotransfected with two vectors: pCMV5 encoding the fusion protein; and pCH110 encoding β -galactosidase at a ratio of 10:1 respectively. It was
5 assumed that using this ratio all, or nearly all, cells transfected with the β -galactosidase vector would also be cotransfected with the expression vector encoding the fusion protein. Control cells were cotransfected with an empty pCMV5 expression vector instead of vector
10 containing the fusion protein construct.

Cells thus cotransfected were stained for detection of β -galactosidase after 24 hrs and after 72 hrs, according to the method of Kolls, et al. (1994). As
15 shown in FIG. 5, control cultures contained abundant quantities of large, blue-staining cells at 24 and 72 hrs post transfection. Cultures cotransfected with either the 55 kDa or 75 kDa TNF receptor\EPOR fusion constructs showed fewer blue cells; about 1/3 as many at 24 hrs and
20 about 1\20 as many at 72 hrs. The blue-staining cells were very small, and appeared to be undergoing condensation, as typically occurs prior to TNF-induced apoptosis.

25 Second, NIH 3T3 cells were cotransfected with two vectors, one encoding either of the two fusion proteins; one in which the Epo receptor extracellular domain was attached to the 55 kDa or 75 kDa TNF receptor cytoplasmic domain, and the other encoding neomycin
30 phosphotransferase (pcDNAneo) which confers resistance to the antibiotic G418. Transfection was accomplished using a ratio of ten parts fusion construct to one part pcDNAneo resistance vector. Cells were then selected for growth in the presence of G418. Cotransfection with
35 either of the two vectors encoding fusion proteins led to a greater-than-ten-fold decrease in the number of G418

- 21 -

resistant colonies that formed over a two-week period of time.

5 Some of the surviving colonies, transfected with each of the two types of fusion construct, exhibited morphology *in vitro* which was suggestive of malignant transformation.

10 In these studies, erythropoietin was added to the cultures continuously at a concentration of 0.5 nM; however, substantially similar results were seen in the absence of added erythropoietin. The inventor had originally considered that the fusion proteins created with an erythropoietin receptor extracellular domain
15 would be biologically inactive under normal conditions in culture, but activated by erythropoietin. Alternatively, an unusual conformation of the fusion protein may lead to dimerization in the absence of added ligand. Regardless of the mechanism, the inventor has shown that the
20 recombinant erythropoietin receptor is active.

 Surprisingly, a considerable amount of cell killing was observed following transfection with the chimeric constructs. To confirm the effect of the recombinant
25 vector, cotransfection studies were established to determine whether fewer cells would express a reporter construct cotransfected with the chimeric expression construct than those cotransfected with an empty vector.

30 Transfections were performed in 293 cells, using a ratio of one part pCH110 (a β -galactosidase-encoding vector) to nine parts of chimeric EpoR encoding plasmid, or empty vector as a control. After 48 hours, cells were stained for β -galactosidase activity as described by
35 Kolls et al., (1994).

- 22 -

Using the wild-type EpoR extracellular domains, fewer than 10% of the number of blue staining cells, as compared with the number in control plates, were consistently observed when cotransfected with the empty
5 vector.

EXAMPLE VIII

FURTHER USES OF CONSTITUTIVELY ACTIVE RECEPTORS

10 When expressed as the products of transgenes driven by tissue specific enhancer/silencer combinations, the constitutively active receptors are contemplated for use in effectively mimicking the tissue-specific expression of TNF. At present, no system for the actual expression
15 of TNF can achieve this, since TNF rapidly emigrates from the site of production.

The present invention also provides for the selective expression of constitutively active modified
20 receptor conjugates in specific tissues within an animal. To achieve this, the modified receptor DNA construct is placed under the control of a cell- or tissue-specific promoter or enhancer/silencer combination, and then administered to an animal. Virtually any means of gene
25 delivery may be employed, such as, for example, an adenoviral or retroviral vector delivery system. Whether or not many cell types receive the construct, the use of a specific genetic control element will result in only specific cells or tissues expressing the constitutively
30 active receptor.

It is envisioned that the delivery of an engineered receptor construct, such as the one described in
Example I, or Example V, to tumor cells *in vivo* may be
35 used to elicit a strongly destructive effect on the tumor cells. Using cell or tissue-specific genetic control elements would mean that the lack of expression of the

- 23 -

recombinant receptors in normal cell types would lead to low toxicity to the host. Therefore, in certain aspects the engineered receptors may be employed as effective chemotherapeutic agents for of cancer treatment. It is
5 recognized that fusion proteins may by themselves have transforming potential. Additionally, the inventor has shown that TNF itself may have transforming activity. The selective cytotoxic action of TNF on tumor cells suggests that it might serve as an effective therapeutic
10 agent if not for its simultaneous ability to activate neutrophils and endothelial cells, which may cause shock. It is possible that this dose-limiting toxicity might be overcome by directing the activity of TNF to the tumor cell population, to the exclusion of neutrophils,
15 endothelial cells and other cells that actively promote an inflammatory response.

As one example, melanoma cells are often sensitive to the cytolytic effect of TNF. Melanoma cells, along
20 with melanocytes and certain neurons, are also unique in that they express sequences placed under the control of a tyrosinase promoter. As such, the inventor contemplates creating an expression vector comprising a constitutively active TNF receptor or TNFR:EpoR receptor under the
25 influence of the tyrosinase promoter. The administration of such a construct into an animal through the use of a viral vector, e.g., adenoviral or other vector, would result in many cells taking up the construct. However, only melanoma cells would succumb to the lethal effect of
30 gene expression, with the melanocytes and neurons would not be expected to react to TNF-mimetic signals because no non-transformed cells are known to be killed by the direct action of TNF, even at extremely high concentrations. One might employ the insulin promoter in
35 the therapy of insulinomas or other tumors capable of utilizing this promoter. The insulin promoter is

- 24 -

expressed in beta-islet cells and their transformed derivatives.

* * *

5

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the composition, methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

- 25 -

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details
5 supplementary to those set forth herein, are specifically incorporated herein by reference.

Chen, C. and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. *Mol.*
10 *Cell. Biol.* 7:2745-2752.

Kolls, J., K. Peppel, M. Silva, and B. Beutler. 1994. Prolonged and effective blockade of TNF activity through adenovirus-mediated gene transfer. *Proc. Natl. Acad.*
15 *Sci.* 91:215-219.

Li, J.P., A.D. D'Andrea, H.F. Lodish, and D. Baltimore. 1990. Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. *Nature* 343:762-764.
20

Longmore, G.D. and H.F. Lodish. 1991. An activating mutation in the murine erythropoietin receptor induces erythroleukemia in mice: a cytokine receptor superfamily oncogene. *Cell* 67:1089-1102.
25

Oyashi, J., Maruyama, K., Liu, Y.-C. and A. Yoshimura. 1994. Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases. *Proc. Natl. Acad. Sci. USA* 91:158-162.
30

Schall, T. J., M. Lewis, K.J. Koller, A. Lee, G.C. Rice, G.H.W. Wong, T. Gatanaga, G. A. Granger, R. Lentz, H. Raab, W.J. Kohr, and D.V. Goeddel. 1990. Molecular
35 cloning and expression of a receptor for human tumor necrosis factor. *Cell* 61:361-370.

- 26 -

Smith, C.A., T. Davis, D. Anderson, L. Solam, M.P.
Beckmann, R. Jerzy, S.K. Dower, D. Cosman, and R.G.
Goodwin. 1990. A receptor for tumor necrosis factor
defines an unusual family of cellular and viral proteins.
Science 248:1019-1023.

- 27 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5 (i) APPLICANT:

NAME: BOARD OF REGENTS, THE UNIVERSITY OF
TEXAS SYSTEM
STREET: 201 West 7th Street
CITY: Austin
10 STATE: Texas
COUNTRY: United States of America
POSTAL CODE: 78701
TELEPHONE NO: (512) 499-4462
TELEFAX: (512) 499-4523

15

(ii) INVENTORS: BEUTLER, Bruce A.
BAZZONI, Flavia M.

(iii) TITLE OF INVENTION: MODIFIED RECEPTORS THAT
20 CONTINUOUSLY SIGNAL

(iv) NUMBER OF SEQUENCES: 8

(v) CORRESPONDENCE ADDRESS:
25 (A) ADDRESSEE: Arnold, White & Durkee
(B) STREET: P.O. Box 4433
(C) CITY: Houston
(D) STATE: Texas
(E) COUNTRY: USA
30 (F) ZIP: 77210

(vi) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
35 (C) OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII
(D) SOFTWARE: WordPerfect 5.1

- 28 -

(vii) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: UNKNOWN
- (B) FILING DATE: CONCURRENTLY HERewith
- (C) CLASSIFICATION: UNKNOWN

5

(viii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US SN 08/224,593
- (B) FILING DATE: 05 APRIL 1994
- (C) CLASSIFICATION: UNKNOWN

10

(ix) ATTORNEY/AGENT INFORMATION:

- (A) NAME: KITCHELL, BARBARA S.
- (B) REGISTRATION NUMBER: 33,928
- (C) REFERENCE/DOCKET NUMBER: UTFD335P--

15

(x) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (512) 418-3000
- (B) TELEFAX: (713) 789-2679
- (C) TELEX: 79-0924

20

(2) INFORMATION FOR SEQ ID NO:1:

25

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

35

CGTGGTACCT GAGCTTCCTG AAGCTAGGGC

30

- 29 -

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GGACCTAAGC TTAGGGTCCA GGTCGCTAGC GGT

33

15

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGACCTAAGC TTCCTCCGCT TGCAAATGTC ACA

33

30

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 30 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

5 GCTCTAGAGC TTATCGCGGG AGGCGGGTCG TGGA

34

(2) INFORMATION FOR SEQ ID NO:5:

10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

20 GGACCTAAGC TTCCAAGCAT CCTTACATCG TTG

33

(2) INFORMATION FOR SEQ ID NO:6:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

35 GCTCTAGATC AGGCCACTTT GACTGCAAT

29

- 31 -

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Leu Asp Pro Phe Glu Leu Pro Pro

1 5

15

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Leu Asp Pro Phe Glu Pro Pro Ile

1 5

30

- 32 -

CLAIMS:

1. A polypeptide comprising a cytokine receptor
5 cytoplasmic domain functionally connected to an
extracellular domain, wherein said extracellular domain
is capable of forming multimers and stimulating
constitutive signal activity in said cytoplasmic domain.
- 10 2. The polypeptide of claim 1, wherein said
multimerizing extracellular domain is a mouse
erythropoietin receptor extracellular domain containing
an arginine to cysteine mutation at position 129.
- 15 3. The polypeptide of claim 1, wherein said cytokine
receptor cytoplasmic domain is a tumor necrosis factor
receptor cytoplasmic domain.
- 20 4. The polypeptide of claim 3, wherein said tumor
necrosis factor receptor is the 55 kDa TNF receptor.
- 25 5. The polypeptide of claim 3, wherein said tumor
necrosis factor receptor is the 75 kDa TNF receptor.
- 30 6. An expression vector construct comprising a DNA
sequence encoding an amino acid sequence in accordance
with SEQ ID NO:7.
- 35 7. The expression vector construct of claim 6, further
comprising a DNA sequence encoding the polypeptide of
claim 1.

- 33 -

8. A method of inducing a cytotoxic effect in a cell comprising the steps of:

5 obtaining an expression vector construct comprising
a cytokine receptor with constitutive signal
activity; and


10 expressing said cytokine receptor in a cell, wherein
said signal activity confers a cytotoxic
reaction.

FIG. 1A



3T3 T-R#1


FIG. 1B



3T3 Ø


1/5

FIG. 1C



3T3 T-R#1 CHX

FIG. 1D



Ø 3T3 CHX

2/5




FIG.2

3/5




FIG. 3

4/5




FIG.4

5/5




FIG.5A

PAM pCMV₄




FIG.5B

PAM wt 75




FIG.5C

PAM wt 55

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/04221

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K14/705 C07K19/00 C12N15/62 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 15322 (THE GENERAL HOSPITAL CORPORATION) 17 September 1992 * Summary of the invention; claims *	1
Y	PROC. NATL. ACAD. SCI. USA, vol. 91, January 1994 pages 158-162, OHASHI, H. ET AL. 'Ligand introduced activation of chimeric receptors between erythropoietin receptor and receptor tyrosine kinase' cited in the application * whole disclosure *	1-8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

6 July 1995

Date of mailing of the international search report

04.08.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Hermann, R

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/04221

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CELL, vol. 67, 1991 pages 1089-1102, LONGMORE, G.D. & LODISH, H.F. 'An activating mutation in the murine Erythropoietin receptor induces erythroleukemia in mice: a cytokine receptor superfamily oncogene' cited in the application * whole disclosure *</p> <p style="text-align: center;">---</p>	1-8
Y	<p>WO,A,93 23550 (GENENTECH) 25 November 1993 * page 4, line 29 - page 5, line 16; claims 1 and 12 *</p> <p style="text-align: center;">---</p>	3-5
A	<p>WO,A,92 10591 (CELL GENESYS, INC.) 25 June 1992</p> <p style="text-align: center;">---</p>	
T	<p>SCIENCE, vol. 264, 29 April 1994 pages 667-668, BEUTLER, B. & VAN HUFFEL, C. 'Unraveling function in the TNF ligand and receptor families'</p> <p style="text-align: center;">-----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/04221

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9215322	17-09-92	AU-A- 1555992	06-10-92
		BR-A- 9205736	27-09-94
		CA-A- 2104957	17-09-92
		CZ-A- 9301840	13-04-94
		EP-A- 0574512	22-12-93
		HU-A- 65631	28-07-94
		JP-T- 6509462	27-10-94
		NO-A- 933169	04-11-93
		NZ-A- 241855	27-04-94
		PT-A- 100207	31-05-94
WO-A-9323550	25-11-93	US-A- 5316921	31-05-94
		US-A- 5328837	12-07-94
		EP-A- 0642580	15-03-95
		EP-A- 0642585	15-03-95
		WO-A- 9323541	25-11-93
WO-A-9210591	25-06-92	AU-B- 643109	04-11-93
		AU-A- 9172291	08-07-92
		EP-A- 0517895	16-12-92
		US-A- 5359046	25-10-94